DocSym
β
Searchsearch
Search
(Y55.1) Skeletal muscle relaxants [neuromuscular blocking agents]
More details coming soon
20 955 in individuals diagnosis skeletal muscle relaxants [neuromuscular blocking agents] confirmed
4 592 deaths with diagnosis skeletal muscle relaxants [neuromuscular blocking agents]
22% mortality rate associated with the disease skeletal muscle relaxants [neuromuscular blocking agents]
Diagnosis skeletal muscle relaxants [neuromuscular blocking agents] is diagnosed Women are 45.26% more likely than Men
5 735
Men receive the diagnosis skeletal muscle relaxants [neuromuscular blocking agents]
0 (less than 0.1%)Died from this diagnosis.
100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
15 220
Women receive the diagnosis skeletal muscle relaxants [neuromuscular blocking agents]
4 592 (30.2 %)Died from this diagnosis.
Risk Group for the Disease skeletal muscle relaxants [neuromuscular blocking agents] - Men aged 0-5 and Women aged 30-34
In Men diagnosis is most often set at age 0-5, 15-19, 35-39, 55-59
Less common in men the disease occurs at Age 0-1, 5-14, 20-34, 40-54, 60-95+Less common in women the disease occurs at Age 0-1, 10-14, 20-29, 35-44, 50-54, 60-64, 70-74, 90-95+
In Women diagnosis is most often set at age 0-9, 15-19, 30-34, 45-49, 55-59, 65-69, 75-89
Disease Features skeletal muscle relaxants [neuromuscular blocking agents]
Absence or low individual and public risk
Skeletal muscle relaxants [neuromuscular blocking agents] - what does this mean
Skeletal muscle relaxants, also known as neuromuscular blocking agents, work by blocking the transmission of nerve impulses to the muscles, thus causing a temporary paralysis of the muscle. this paralysis can be used for medical procedures, such as intubation and surgery, as well as for treating muscle spasms and spasticity.
What happens during the disease - skeletal muscle relaxants [neuromuscular blocking agents]
Skeletal muscle relaxants, or neuromuscular blocking agents, work by blocking the transmission of nerve impulses to the muscle, resulting in a decreased response to nerve stimulation. this blockage occurs at the neuromuscular junction, where the nerve and muscle fibers come into contact. the blocking agents bind to the acetylcholine receptors of the muscle fibers, preventing the release of acetylcholine, which is the neurotransmitter responsible for relaying the nerve impulse. this leads to a decrease in muscle contraction and thus a relaxation of the muscle.
Clinical Pattern
More details coming soon
How does a doctor diagnose
More details coming soon
Treatment and Medical Assistance
More details coming soon
7 Days of Hospitalization Required
Average Time for Outpatient Care Not Established
Skeletal muscle relaxants [neuromuscular blocking agents] - Prevention
The primary prevention of skeletal muscle relaxants [neuromuscular blocking agents] is to avoid exposure to any environment that may contain these agents. this includes avoiding contact with people who have been exposed to these agents or any objects that have been contaminated by them. additionally, proper hygiene and sanitation practices should be followed to reduce the risk of exposure.